Biopharmaceutical corporations like AbbVie are not categorically exempt from general import tariffs or cross-border trade duties affecting physical raw materials, chemical components, or specialized manufacturing equipment. However, pharmaceutical products frequently navigate distinct regulatory frameworks under international trade agreements and healthcare exemptions compared to traditional heavy industrial goods.